FORTHCOMING DEADLINES: J&W Announces Class Action Suits against Forterra, Inc., Foundation Medicine, Inc., Teva Pharmaceutical Industries Limited and Dr. Reddys Laboratories Limited; Investors Encouraged to Contact Firm

SAN DIEGO, Sept. 2, 2017 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential claims against Forterra, Inc., Foundation Medicine, Inc., Teva Pharmaceutical Industries Limited, and Dr. Reddys Laboratories Limited as detailed below:

Forterra, Inc.
Johnson & Weaver, LLP (J&W) reminds investors that a class action case was filed against Forterra, Inc. (NASDAQ: FRTA) ("Forterra") for purchasers of the stock between October 19, 2016 and May 12, 2017 or traceable to the Company's Initial Public Offering ("IPO").

The complaint alleges that the Registration Statement used to conduct the IPO contained inaccurate statements and omitted facts necessary to make other statements made therein not misleading. Among other things, the Registration Statement failed to disclose, at the time of the IPO, that organic sales in Forterra's Drainage and Water segments had significantly declined, that Forterra was experiencing increased pricing pressure due to competition and continued softness in its concrete and steel pipe business, that Forterra had been losing business in its important pipe and precast business due to in large part to operational problems at its production plants, and that Forterra had undisclosed material weaknesses in its internal controls that prevented it from accurately reporting and forecasting its financial results.

If you wish to serve as lead plaintiff, you have until October 13, 2017 to request that the Court appoint you as lead plaintiff.

If you purchased Forterra stock between October 19, 2016 and May 12, 2017, and are interested in learning more about your legal rights and remedies, please contact Jim Baker ([email protected]) at 619-814-4471. If you email, please include your phone number.

Foundation Medicine, Inc.
Johnson & Weaver, LLP reminds investors that a class action case was filed against Foundation Medicine, Inc. (NASDAQ: FMI) ("Foundation Medicine") for purchasers of the stock between February 26, 2014 through November 3, 2015, inclusive (the "Class Period").

The complaint filed in this class action alleges that the defendants made false and misleading statements regarding; (1) the reimbursement process and likelihood of coverage for Foundation Medicine's tumor tests by Medicare; and (2) Foundation Medicine's financial guidance. As a result of these alleged false statements, Foundation Medicine common stock traded at artificially inflated prices during the Class Period.

If you purchased shares during the Class Period and suffered a loss in Foundation Medicine, you have until September 26, 2017 to request that the Court appoint you as lead plaintiff.

If you are a long-term shareholder of Foundation Medicine shares and continuously held shares before February 26, 2014, you may have standing to hold Foundation Medicine harmless from the damage the officers and directors may have caused by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.

If you are a Foundation Medicine shareholder and are interested in learning more about your legal rights and remedies, please contact Jim Baker ([email protected]) at 619-814-4471. If you email, please include your phone number.

Teva Pharmaceutical Industries Limited
Johnson & Weaver, LLP reminds investors that a class action case was filed against Teva Pharmaceutical Industries Limited (NYSE: TEVA) ("TEVA") for purchasers of the stock between November 15, 2016 and August 2, 2017, inclusive (the "Class Period").

The complaint alleges that during the Class Period, defendants made false and/or misleading statements and failed to disclose that the poor performance of Teva's U.S. generics business resulted in Teva's recording a goodwill impairment charge related to the acquisition of Actavis Generics and was a key factor in cutting Teva's dividend by 75%. When this news was disclosed, shares of Teva declined significantly, which, according to the lawsuit, caused investors harm.

If you purchased shares during the Class Period and suffered a loss in Teva, you have until October 23, 2017, to request that the Court appoint you as lead plaintiff.

If you are interested in learning more about your legal rights and remedies or becoming a lead plaintiff in this case, please contact analyst Jim Baker ([email protected]) at 619-814-4471.  If you email, please include your phone number.

Dr. Reddys Laboratories Limited
Johnson & Weaver, LLP reminds investors that a class action case was filed against Dr. Reddys Laboratories Limited (NYSE: RDY) ("Dr. Reddys") for purchasers of the stock between June 17, 2015 and August 10, 2017, inclusive (the "Class Period").

The complaint alleges that during the Class Period, defendants made false and misleading statements and failed to disclose that; (1) Dr. Reddy's lacked an effective corporate quality system; and (2) as a result, defendants' public statements were materially false and misleading at all relevant times.

On August 10, 2017, Dr. Reddy's disclosed that the Regulatory of Germany did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary Betapharm Arzneimittel, located in Hyderabad, India, following a recent inspection of the plant.

If you purchased shares during the Class Period and suffered a loss in Teva, you have until October 24, 2017 to request that the Court appoint you as lead plaintiff.

If you are interested in learning more about your legal rights and remedies or becoming a lead plaintiff in this case, please contact analyst Jim Baker ([email protected]) at 619-814-4471.  If you email, please include your phone number.

About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
[email protected]

SOURCE Johnson & Weaver, LLP

Related Links

http://johnsonandweaver.com